Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-ar
Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents.
200000 (raw units)
price
1
calls / 30d
1
unique payers
2026-08-20
updated
Provider
clinicalintelpulse.theaslangroupllc.com · discovered, not yet claimed by its owner
Payment (x402 accepts[])
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "200000",
"maxTimeoutSeconds": 604900
},
{
"scheme": "exact",
"network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
"payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
"asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:137",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:42161",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:480",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:143",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:196",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:999",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
"payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
"asset": "31566704",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "XRP",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "524C555344000000000000000000000000000000",
"amount": "0.2",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:56",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
"amount": "200000000000000000",
"maxTimeoutSeconds": 300
}
]Output schema
{
"bazaar": {
"info": {
"input": {
"method": "GET",
"queryParams": {
"focus": "pipeline | approvals | deals | all (default: all)",
"lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
"sponsor": "Company name — e.g. \"Moderna\" | \"BioNTech\" | \"Alnylam\" | \"Vertex Pharmaceuticals\" | \"Regeneron\""
},
"type": "http"
},
"output": {
"example": {
"competitive_position": "Global leader in RNAi therapeutics. 6 approved drugs. Patent portfolio dominant through 2035+.",
"fda_approvals": [
{
"approved": "2018",
"drug": "Patisiran (Onpattro)",
"first_in_class": true,
"indication": "hATTR polyneuropathy",
"type": "NDA"
},
{
"approved": "2019",
"drug": "Givosiran (Givlaari)",
"indication": "Acute hepatic porphyria",
"type": "NDA"
}
],
"investment_signals": {
"near_term_catalysts": [
"HELIOS-B ATTR-CM readout 2025",
"ALN-APP Phase 2 for early Alzheimer's"
],
"pipeline_value_estimate": "$12-18B risk-adjusted NPV",
"risks": [
"Pricing pressure in rare disease",
"RNAi delivery competition from Arrowhead"
]
},
"partnership_activity": "Novartis partnership (inclisiran, cardiovascular) — $9.7B deal. Roche collaborations ongoing. Regeneron RNAi collaboration $400M+.",
"phase3_assets": [
{
"completion": "2025-Q3",
"condition": "ATTR Cardiomyopathy",
"drug": "Vutrisiran (Amvuttra)",
"nctId": "NCT04153149",
"significance": "Key label expansion into ATTR-CM — $3B+ market",
"status": "ACTIVE_NOT_RECRUITING"
}
],
"pipeline_summary": {
"phase1_count": 8,
"phase2_count": 9,
"phase3_count": 6,
"primary_therapeutic_areas": [
"Rare genetic diseases (TTR, PH1, AHP)",
"Cardiovascular (inclisiran)",
"CNS (Huntington's)"
],
"total_active_trials": 23
},
"query_summary": {
"focus": "all",
"sponsor": "Alnylam Pharmaceuticals"
}
},
"type": "json"
}
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"properties": {
"input": {
"additionalProperties": false,
"properties": {
"method": {
"enum": [
"GET",
"HEAD",
"DELETE"
],
"type": "string"
},
"queryParams": {
"properties": {
"focus": {
"type": "string"
},
"lang": {
"type": "string"
},
"sponsor": {
"type": "string"
}
},
"type": "object"
},
"type": {
"const": "http",
"type": "string"
}
},
"required": [
"type",
"method"
],
"type": "object"
},
"output": {
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}
},
"required": [
"input"
],
"type": "object"
}
},
"builder-code": {
"info": {
"a": "bc_gxy6qn5p"
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"additionalProperties": false,
"properties": {
"a": {
"description": "App builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"s": {
"description": "Service builder codes",
"items": {
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"type": "array"
},
"w": {
"description": "Wallet builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
}
},
"type": "object"
}
}
}Use it
curl
curl "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel" # -> 402 Payment Required, accepts[] lists how to pay # retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paid
JavaScript
const res = await fetch("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}Python
import httpx
res = httpx.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerMachine-readable
Everything on this page is also available as clean JSON at /resources/4550.json, and this resource appears in /discovery/resources and /discovery/search.